EGFR protein, as assessed by immunohistochemistry, was overexpressed in 76% of tumours (data not shown) and did not correlate with response to cetuximab as previously demonstrated in other studies (Cunningham et al, 2004; Saltz et al, 2004; Chung et al, 2005). The gene discussed is EGFR; the disease is neoplasm.